Who are Alleance®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Retaine™, Cationorm single-dose eye drop, Refresh Relieva PF, TheraTears® Lubricant Eye Drop, REFRESH LIQUIGEL®, PEG- 400 based artificial tear.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/alleance.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Alleance® — Competitive Intelligence Brief

Alleance® (Alleance®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Artificial tear / Ocular lubricant. Area: Ophthalmology.

phase 3 Artificial tear / Ocular lubricant Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Alleance® (Alleance®) — Laboratorios Sophia S.A de C.V.. Alleance® is an ophthalmic formulation designed to treat dry eye disease by lubricating and protecting the ocular surface.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Alleance® TARGET	Alleance®	Laboratorios Sophia S.A de C.V.	phase 3	Artificial tear / Ocular lubricant
Retaine™	Retaine™	Ocusoft, Inc.	marketed	Artificial tear / ocular lubricant
Cationorm single-dose eye drop	Cationorm single-dose eye drop	Nguyen Viet Giap	marketed	Artificial tear / ocular lubricant
Refresh Relieva PF	Refresh Relieva PF	University of California, Berkeley	marketed	Artificial tear / Ocular lubricant
TheraTears® Lubricant Eye Drop	TheraTears® Lubricant Eye Drop	University of Waterloo	marketed	Artificial tear / Ocular lubricant
REFRESH LIQUIGEL®	REFRESH LIQUIGEL®	Allergan	marketed	Artificial tear / ocular lubricant
PEG- 400 based artificial tear	PEG- 400 based artificial tear	Bp Consulting, Inc	marketed	Artificial tear / Ocular lubricant

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Artificial tear / Ocular lubricant class)

Laboratorios Sophia S.A de C.V. · 7 drugs in this class
Allergan · 3 drugs in this class
University of Waterloo · 2 drugs in this class
University of California, Berkeley · 2 drugs in this class
Bp Consulting, Inc · 1 drug in this class
Chong Kun Dang Pharmaceutical · 1 drug in this class
Clinica Oftamologica Zona Sul · 1 drug in this class
Fundação Altino Ventura · 1 drug in this class
Medical University of South Carolina · 1 drug in this class
Ocuwize LTD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Alleance® — Competitive Intelligence Brief. https://druglandscape.com/ci/alleance. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab